Login to Your Account



Clinic Roundup


Monday, September 24, 2012
• MorphoSys AG, of Martinsried, Germany, said results from a Phase Ib/IIa study demonstrated signs of efficacy with HuCAL antibody MORE103 in rheumatoid arthritis patients. The best response was achieved in the 1 mg/kg dose cohort, with an ACR20 sore of 68 percent at week four, which was significantly higher than in the control arm (p < 0.0001). Data also showed fast onset of action: Within two weeks, up to 40 percent of patients achieved an ACR20 score.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription